Jeffrey Epstein New York Continues its Avid Support of Mount Sinai's Pioneering Research in Breast Cancer.
The Jeffrey Epstein VI Foundation has been a long standing supporter of Mount Sinai's cutting edge research in breast cancer. The foundation has directly funded both the renowned Dubin Breast Center at Mount Sinai as well as independent research at the Icahn School of Medicine. In the past year, several exciting initiatives in breast cancer research at Mount Sinai are changing the very approach to battling the disease.
3D Mammograms for Breast Cancer:
Approximately two years ago, the Dubin Breast Center adopted the use of 3D mammography for the detection of breast cancer. The 3 dimensional machines have been instrumental in helping women identify and isolate the presence of breast tumors. 3D mammography was created as Mass General Hospital in Boston. Also called tomosynthesis, it was FDA approved in February 2011. 3D mammography has numerous benefits to its 2D counterpart. Firstly the 3D method takes about 60 images per test as opposed to 1 with 2D mammography. Secondly, images are transferred to 1mm digital slices allowing radiologists to see the compilation from all angles in a three dimensional format. 2D mammography continues to be an essential test in saving lives however, 3D mammography can better detect tumor tissue that is harder to see in dense, fibrous breasts. 3D mammography has also reduced the percentage of false positives, helping radiologists identify cysts and calcification that might otherwise be confused for a tumor under a 2D test. Doctors can also get a better sense of a tumor's topography with a 3D mammogram: notably how it grows and spreads. The Dubin Breast Center is part of the Tisch Cancer Institute, located on the Mount Sinai Icahn School of Medicine campus and houses a wide variety of highly advanced services from prevention to eradicating the disease.
Clues from Breast Wound Fluid:
The Jeffrey Epstein VI Foundation has financed critical new research at Mount Sinai which looks at the content of mastectomy breast wound fluid for clues about breast metastais. Led by the reconstructive surgeon Dr. Jess Ting, breast oncologist, Dr. Kerin Adelson and molecular biologist, Dr. Doris Germain , the team are discovering that breast cancer metastasis might not necessarily emanate from the tumor but from its micro-environment. This change in origin is essential Dr. Ting explains because doctors can better identify those patients at greater risk of metastasis post-surgery, providing a better opportunity for prevention. To analyze the surrounding breast tissue of a tumor, Dr Ting and his colleagues use the unique method of studying the wound fluid that typically drains from a post-mastectomy site. Up to now, clinical data of a cancer's tissue environment has been the blood, a rich source of disease-related biomarkers. However, blood's dense and complex composition, has been a major challenge for biomarker assays. Other body fluids, such as urine, cerebrospina, bronchoalveolar lavage, synovial, amniotic, seminal plasma and interstitial fluids are also rich in disease biomarkers but are only informative in advanced metastatic cancer patients, offering limited prognostic value in term of disease progression. Wound fluid emitted from a draining tube, contains all the proteins, growth factors and cytokines secreted by the cells around the cancer providing an ideal way of studying the microenvironment in vivo. Wound fluid from a breast cancer patient also has the unique advantage of having an exact comparative control specimen from the non-cancerous breast which is often removed as a precaution measure. Indeed, over the last two years, Dr. Ting and his team have found distinct and revealing differences between the cancerous wound fluid and non-cancerous; both in vitro and in mice.
Jeffrey Epstein Backs Pivotal Findings in Breast Wound Tissue at Mount Sinai